1. Home
  2. DVAX vs VSTS Comparison

DVAX vs VSTS Comparison

Compare DVAX & VSTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • VSTS
  • Stock Information
  • Founded
  • DVAX 1996
  • VSTS 1936
  • Country
  • DVAX United States
  • VSTS United States
  • Employees
  • DVAX N/A
  • VSTS N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • VSTS
  • Sector
  • DVAX Health Care
  • VSTS
  • Exchange
  • DVAX Nasdaq
  • VSTS Nasdaq
  • Market Cap
  • DVAX 1.5B
  • VSTS 1.8B
  • IPO Year
  • DVAX 2004
  • VSTS N/A
  • Fundamental
  • Price
  • DVAX $12.21
  • VSTS $13.86
  • Analyst Decision
  • DVAX Buy
  • VSTS Buy
  • Analyst Count
  • DVAX 2
  • VSTS 8
  • Target Price
  • DVAX $22.00
  • VSTS $15.78
  • AVG Volume (30 Days)
  • DVAX 3.3M
  • VSTS 1.2M
  • Earning Date
  • DVAX 11-07-2024
  • VSTS 11-21-2024
  • Dividend Yield
  • DVAX N/A
  • VSTS 1.01%
  • EPS Growth
  • DVAX N/A
  • VSTS N/A
  • EPS
  • DVAX 0.15
  • VSTS 0.89
  • Revenue
  • DVAX $260,810,000.00
  • VSTS $2,837,440,000.00
  • Revenue This Year
  • DVAX $23.13
  • VSTS $1.62
  • Revenue Next Year
  • DVAX $19.60
  • VSTS $1.43
  • P/E Ratio
  • DVAX $80.80
  • VSTS $15.54
  • Revenue Growth
  • DVAX N/A
  • VSTS 1.61
  • 52 Week Low
  • DVAX $9.74
  • VSTS $8.92
  • 52 Week High
  • DVAX $15.01
  • VSTS $22.37
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 52.22
  • VSTS 43.08
  • Support Level
  • DVAX $11.61
  • VSTS $13.94
  • Resistance Level
  • DVAX $13.74
  • VSTS $14.47
  • Average True Range (ATR)
  • DVAX 0.52
  • VSTS 0.40
  • MACD
  • DVAX 0.09
  • VSTS 0.04
  • Stochastic Oscillator
  • DVAX 32.80
  • VSTS 51.59

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

Share on Social Networks: